# Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

> **NCT06510582** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Cooper Health System** · enrollment: 140 (estimated)

## Conditions studied

- Chronic Subdural Hematoma

## Interventions

- **DRUG:** Bevacizumab 2 mg/kg
- **DRUG:** Bevacizumab 4 mg/kg

## Key facts

- **NCT ID:** NCT06510582
- **Lead sponsor:** The Cooper Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06510582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06510582, "Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06510582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*